A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer Meeting Abstract

  

Authors:	Isakoff, S. J.; Pulhalla, S.; Shepherd, S. P.; Falotico, N.; Kaufman, B.; Friedlander, M.; Robson, M.; Domchek, S.; Garber, J.; McKeegan, E.; Chyla, B.; Qian, J.; Giranda, V. L.
Abstract Title:	A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer
Meeting Title:	35th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)
Journal Title:	Cancer Research
Volume:	72
Issue:	24 Suppl.
Meeting Dates:	2012 Dec 4-8
Meeting Location:	San Antonio, TX
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2012-12-15
Language:	English
ACCESSION:	WOS:000209704901088
DOI:	10.1158/0008-5472.sabcs12-ot2-3-07
PROVIDER:	wos
Notes:	Meeting Abstract: OT2-3-07 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/99008